CompletedNCT01357993
A Long-Term Study on Safety of JNS001 in Adults With Attention-Deficit Hyperactivity Disorder
Researchers studied JNS001, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Medication studyAges 18–65Japan
Understand this study
What did researchers investigate?
Researchers studied JNS001, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
- Listed locations
- Chiba and 28 more locationsSee all locations and recruitment
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
Study information
Study start dateMay 2011
- Recruitment status
- Completed
- Enrollment listed in the registry
- 253
- Sponsor
- Janssen Pharmaceutical K.K.
- Sponsor type
- Pharmaceutical company
- Study type
- Drug
- Intervention type
- Medication / drug
- Study phase
- Phase 3Usually a larger study designed to confirm effectiveness and safety in a broader group.
- Locations
- Japan
- Age range
- From 18 Years to 65 Years
- Official registry ID
- NCT01357993
- Official title
Show the full official title
An Open-Label, Dose-Titration, Long-Term Study to Evaluate the Safety of JNS001 in Adults With Attention-Deficit/Hyperactivity Disorder at Doses of 18 mg, 27 mg, 36 mg, 45 mg, 54 mg, 63 mg or 72 mg Per Day
Recruitment & locations
CompletedChiba · Chigasaki · Chiyoda City
26 more locations
- Fuchū
- Fukuoka
- Fukushima
- Hamamatsu
- Higashiosaka
- Ichikawa
- Iruma
- Isehara
- Kashihara
- Kishiwada
- Kobe
- Kumamoto
- Kurume
- Matsuyama
- Nagasaki
- Nagoya
- Nara
- Neyagawa
- Osaka
- Saitama
- Sakai
- Sapporo
- Shibuya City
- Takatsuki
- Tokyo
- Yokohama
Questions about this study
What did researchers investigate?
Researchers studied JNS001, tracking side effects to assess long-term safety and tolerability in adults with ADHD.
Who is behind this study?
The study sponsor is Janssen Pharmaceutical K.K., a pharmaceutical company.
Did this study involve medication?
Yes. The study involved medication, including JNS001.
Who was this study for?
This study was for people with ADHD. Listed age limits: 18 years to 65 years. Other eligibility criteria applied.
Want to find a study that may fit you better?
Answer a few simple questions to explore HopeStage studies by condition, country, and situation.
Find a study that may fit me